Cytokinetics
CYTK
136 hedge funds and large institutions have $465M invested in Cytokinetics in 2017 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 53 increasing their positions, 27 reducing their positions, and 13 closing their positions.
215% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 13
123% more call options, than puts
Call options by funds: $5.24M | Put options by funds: $2.35M
96% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 27
27% more capital invested
Capital invested by funds: $366M → $465M (+$98.8M)
26% more funds holding
Funds holding: 108 → 136 (+28)
10.64% more ownership
Funds ownership: 68.21% → 78.84% (+11%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$44.6M |
| 2 |
Janus Henderson Group
London,
|
+$37.3M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$17.9M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.2M |
| 5 |
State Street
Boston,
Massachusetts
|
+$10.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$31.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$14.3M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$10.1M |
| 4 |
Millennium Management
New York
|
-$5.04M |
| 5 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$2.76M |
CYTK Hedge Fund Activity: Q2 2017 in Review
136 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q2 2017, worth a combined $465M — up 27% from $366M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new CYTK positions and 13 closed out — a net gain of 28 holders — while 53 added to existing stakes and 27 trimmed.
The largest buyer was BlackRock, adding an estimated $44.6M. The largest seller was BVF Inc, cutting an estimated $31.6M.
- 136 institutional investors held Cytokinetics (CYTK) as of Q2 2017, up from 108 in Q1 2017.
- Funds reported $465M of Cytokinetics stock for Q2 2017, up 27% quarter-over-quarter.
- 41 funds opened new Cytokinetics positions in Q2 2017 and 13 closed out, a net change of +28 holders.
- The largest Cytokinetics buyer in Q2 2017 was BlackRock, an estimated $44.6M added.
- The largest Cytokinetics seller in Q2 2017 was BVF Inc, an estimated $31.6M sold.
Based on aggregated 13F filings for Q2 2017.